Overweight and obesity - Risk factors of the development and progression of renal disease;Nadváha a obezita - Faktory podmieňujúce vývin a progresiu ochorení obličiek

Vnitrni Lekarstvi

Volumn 50, Issue 7, 2004, Pages 544-549

  Šebeková, Katarína ^a   Klassen, A ^b   Bahner, U ^b   Heidland, A ^b  

^a SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^b Kuratorium Pre Dialyzu/Transpl O   (Germany)

Author keywords

Diabetic nephropathy; Glomerulosclerosis; Hypertension; Metabolic syndrome; Obesity; Weight reduction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LEPTIN; SODIUM;

ADRENERGIC NERVE; BLOOD CLOTTING; CAPILLARY PRESSURE; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; MICROALBUMINURIA; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM RETENTION; WEIGHT REDUCTION;

DIABETES COMPLICATIONS; HUMANS; KIDNEY; KIDNEY DISEASES; OBESITY; RISK FACTORS;

EID: 3142544234     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Abrass, C. K., Spicer, D., Raugi, G. J.: Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int. 1995; 47: 25-37
2. Allison, D. B., Fontaine, K. R., Manson, J. E. et al.: Annual deaths attributable to obesity in the United States. JAMA 1999, 282: 1530-1538
3. Baigent, C., Burbury, K., Wheeler, D.: Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
4. Bonnet, F., Deprele, C., Sassolas, A. et al.: Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am. J. Kidney Dis. 2001; 37 (4): 720-727
5. Bray, G. A., Tartaglia, L. A.: Medicinal strategies in the treatment of obesity. Nature 2000, 404: 672-677
6. Calle, E. E., Thun, M. J., Petrelli, J. M. et al.: Body-mass index and mortality in a prospective cohort of U.S. adults. N. Engl. J. Med. 1999, 341: 1097-1105
7. Chagnac, A., Weinstein, T., Korzets, A. et al.: Glomerular hemodynamics in severe obesity. Am. J. Physiol. Renal Physiol. 2000; 278: F817-F822
8. Chow, W.-H., Gridley, G., Fraumeni, J. F. Jr. Et al.: Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 2000; 343 (18):1305-1311
9. Clunk, J. M., Lin, C. Y., Curtis, J. J.: Variables affecting weight gain in renal transplant recipients. Am. J. Kidney Dis. 2001, 38: 349-353
10. Culleton, B. F., Larson, M. G., Parfrey, P. S. et al.: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am. J. Med. 2000; 109: 1-8
11. DeFronzo, R. A.: The effect of insulin on renal sodium metabolism. Diabetologia 1981; 21: 165-170
12. Dorpfeld, L. P., Maxwell, M. H., Waks, P. et al.: Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int. J. Obes. 1985, 9: 381-389
13. Döring, A., Hense, H.-W., Stieber, J.: Prävalenz des Übergewichts - Ergebnisse in einer süddeutschen Bevölkerung im nationalen Vergleich. München Med. Wochenschr. 1992; 30: 480-482
14. DPPRG, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393-403
15. Dyer, A. R., Elliott, P., Shipley, M. for the INTERSALT Cooperative Study group: Body mass index versus height and weight in relation to blood pressure - findings for the 10 079 persons in the INTERSALT Study. Am. J. Epidemiol. 1990, 131: 589-596
16. Engeli, S., Negrel, R., Sharma, A. M.: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277
17. Foley, R. N., Parfey, P. S., Sama, M. J.: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998, S3: S112-S119
18. Haynes, W. G., Sivitz, W. I., Morgan, D. A. et al.: Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30 (part 2): 619-623
19. Henegar, J. R., Bigler, S. A., Henegar, L. K. et al.: Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 2001, 12: 1211-1217
20. Johnson, C. P., Gallagher-Lepak, S., Zhu, Y. R. et al.: Factors influencing weight gain after transplantation. Transplantation 1993, 56: 822-827
21. Kambham, N., Markowitz, G. S., Valeri, A. M. et al.: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001; 59: 1498-1509
22. Ketteler, M., Bongantz, P., Westenfeld, R. et al.: Association of low fetuin-A (AHSG) concentration in serum with cardiovascular mortality in patients on dialysis: cross-sectional study. Lancet 2003, 361: 827-833
23. Kincaid-Smith, P.: Hypothesis: focal and segmental glomerulosclerosis related to obesity and the insulin resistance syndrome plays a major role in end-stage renal disease labeled as "hypertensive nephrosclerosis". (Abstrakt). Nephrol. Dial. Transplant. 2003, 18, Suppl. 4: T251, 361
24. Landsberg, L., Young, J. B.: Fasting, feeding and regulation of the sympathetic nervous system. N. Engl. J. Med. 1978, 298: 1295-1301
25. Londe, S., Bourgognie, J. J., Robson, A. M. et al.: Hypertension in apparently normal children. J. Pediatr. 1971; 78: 569-603
26. Maddox, D. A., Alavi, F. K., Santella, R. N. et al.: Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int. 2002; 62: 208-219
27. Meier-Kriesche, H. U., Andorfer, J. A., Kaplan, B.: The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73 (1): 70-74
28. Mogensen, C. E.: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984; 310: 356-360
29. Moller, H., Mellemgaard, A., Lindvig, K. et al.: Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer 1994; 30A: 344-350
30. Morales, E., Valero, M. A., Léon, M. et al.: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am. J. Kidney Dis. 2003, 41: 319-327
31. Perna, A. F., Ingrosso, D., Lombardi, C. et al.: Homocysteine in uremia. Am. J. Kidney Dis. 2003, 41 (S1): S123-S126
32. Pirch, J. D.: Influence of obesity on transplants outcome. ASN renal Week 2003, Sylabus, 471-484
33. Praga, M., Hernández, E., Andres, A. et al.: Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70: 34-41
34. Praga, M., Hernández, E., Herrero, J. C. et al.: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000; 58: 2111-2118
35. Praga, M., Hernández, E., Morales, E. et al.: Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2001; 16: 1790-1798
36. QuaSi-Niere Jahresbericht 2001/2002
37. Reaven, G.: Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288
38. Ribstein, J., du Cailar, G., Mimran, A.: Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-615
39. Riser, B. L., Cortes, P., Heilig, C. et al.: Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am. J. Pathol. 1999; 148: 1915-1923
40. Ritz, E., Lippert, J., Keller, C.: Rapider Anstieg der Zahl niereninsuffizienter Typ-II-Diabetiker: nicht nur ein Problem der Nephrologen. Dtsch. Med. Wschr. 1996; 121: 1247
41. Ritz, E., Rychlík, I., Locatelli, F. et al.: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 1999; 34: 795-808
42. Schinzel, R., Munch, G., Heidland, A. et al.: Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001, 87: 295-303
43. Sharma, A. M., Janke, J., Gorzelniak, K. et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611
44. Sowers, J. R., Whitfield, L. A., Catania, R. A. et al.: Role of the sympathetic nervous system in blood pressure maintenance in obesity. J. Clin. Endocrinol. Metab. 1982; 54: 1181-1185
45. Stamler, R., Stamler, J., Riedlinger, W. F. et al.: Weight and blood pressure. J. Am. Med. Assoc. 1987, 240: 1607
46. Stehouwer, C. D., Nauta, J. J., Zeldenrust, G. C. et al.: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323
47. Tchernof, A., Nolan, A., Sites, C. K. et al.: Weight loss reduces C-reactive protein levels in obese post-menopausal women. Circulation 2002, 105: 564-569
48. Tozawa, M., Iseki, K., Iseki, C. et al.: Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002; 62: 956-962
49. Tuck, M. L., Sowers, J., Dornfeld, L. et al.: The effects of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 1981, 304: 930-933
50. Tuolemihto, K., Lindström, J., Erikson, J. G. et al., Finnish diabetes prevention group study. Prevention of type 2 diabetes mellitus by changes in life style among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344: 1343-1350
51. USRDS, United States Renal Data System. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, in National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: 2001
52. Weidmann, P., de Courten, M., Boehlen, L. et al.: The pathogenesis of hypertension in obese subjects. Drugs 1993; 46 (Suppl. 2): 197-209
53. Weinsier, R. L., James, L. D., Darnell, B. E. et al.: Obesity-related hypertension: evaluation of the separate effects of energy restriction and weight reduction on hemodynamic and neuroendocrine status. Am. J. Med. 1991, 90: 460-468
54. Weisinger, J. R., Kempson, R. L., Eldrige, F. L. et al.: The nephrotic syndrome: a complication of massive obesity. Ann. Int. Med. 1974, 81: 440-447
55. Wolf, G.: "Lasst wohlbeleibte Männer um mich sein": Leptin und Nierenerkrankungen. Nieren- und Hochdruckkrankh 2002; 31 (4): 163-171
56. Wolf, G., Chen, S., Han, D. C. et al.: Leptin and renal disease. Am. J. Kidney Dis. 2002; 39 (1): 1-11
57. Wong, J. S., Port, F. K., Hulbert-Shearon, T. E. et al.: Survival advantage in Asian-American end-stage renal disease patients. Kidney Int. 1999, 55: 2515-2523
58. Zocalli, C., Bode-Boger, S., Mallamaci, F. et al.: Plasma concentration of asymetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358: 2113-2117
59. Zocalli, C.: Cardiovascular risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol. Dial. Transplant. 2002, 17 (S11): S50-S54